BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32556643)

  • 1. Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients.
    Liang LY; Wong VW; Toyoda H; Tse YK; Yip TC; Yuen BW; Tada T; Kumada T; Lee HW; Lui GC; Chan HL; Wong GL
    J Gastroenterol; 2020 Sep; 55(9):899-908. PubMed ID: 32556643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    Aliment Pharmacol Ther; 2019 Feb; 49(4):457-471. PubMed ID: 30663078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy.
    Cheung KS; Seto WK; Wong DK; Lai CL; Yuen MF
    J Viral Hepat; 2017 Aug; 24(8):654-661. PubMed ID: 28185363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients.
    Kaneko S; Kurosaki M; Inada K; Kirino S; Hayakawa Y; Yamashita K; Osawa L; Sekiguchi S; Higuchi M; Takaura K; Maeyashiki C; Tamaki N; Yasui Y; Itakura J; Takahashi Y; Tsuchiya K; Nakanishi H; Izumi N
    J Gastroenterol Hepatol; 2021 Oct; 36(10):2943-2951. PubMed ID: 34057248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.
    Wang B; Carey I; Bruce M; Montague S; Dusheiko G; Agarwal K
    J Viral Hepat; 2018 Aug; 25(8):886-893. PubMed ID: 29532589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance.
    Lee HW; Lee JI; Kim S; Kim S; Chang HY; Lee KS
    BMC Gastroenterol; 2020 Apr; 20(1):113. PubMed ID: 32305059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy.
    Chuaypen N; Posuwan N; Chittmittraprap S; Hirankarn N; Treeprasertsuk S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Clin Microbiol Infect; 2018 Mar; 24(3):306.e7-306.e13. PubMed ID: 28750917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining Hepatitis B Virus RNA and Hepatitis B Core-Related Antigen: Guidance for Safely Stopping Nucleos(t)ide Analogues in Hepatitis B e Antigen-Positive Patients With Chronic Hepatitis B.
    Fan R; Peng J; Xie Q; Tan D; Xu M; Niu J; Wang H; Ren H; Chen X; Wang M; Sheng J; Tang H; Bai X; Wu Y; Zhou B; Sun J; Hou J;
    J Infect Dis; 2020 Jul; 222(4):611-618. PubMed ID: 32211776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection.
    Mak LY; Wong DK; Cheung KS; Seto WK; Lai CL; Yuen MF
    Aliment Pharmacol Ther; 2018 Jan; 47(1):43-54. PubMed ID: 29035003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma.
    To WP; Mak LY; Wong DK; Fung J; Liu F; Seto WK; Lai CL; Yuen MF
    J Viral Hepat; 2019 Dec; 26(12):1473-1480. PubMed ID: 31418973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultrasensitive Assay for Hepatitis B Core-Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir.
    Hosaka T; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Akuta N; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    Hepatol Commun; 2022 Jan; 6(1):36-49. PubMed ID: 34532993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three heads are better than two: Hepatitis B core-related antigen as a new predictor of hepatitis B virus-related hepatocellular carcinoma.
    Wu JW; Kao JH; Tseng TC
    Clin Mol Hepatol; 2021 Oct; 27(4):524-534. PubMed ID: 33618507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HBcrAg Predicts Hepatocellular Carcinoma Development in Chronic B Hepatitis Related Liver Cirrhosis Patients Undergoing Long-Term Effective Anti-Viral.
    Chang KC; Lin MT; Wang JH; Hung CH; Chen CH; Chiu SY; Hu TH
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy.
    Wang ML; Deng R; Chen EQ; Tao CM; Liao J; Zhou TY; Wang J; Tang H
    Clin Res Hepatol Gastroenterol; 2019 Jun; 43(3):301-309. PubMed ID: 30497844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B virus core-related antigen (HBcrAg) as a prognostic marker for the development of hepatocellular carcinoma: A mini systematic review of the literature.
    Afifi AM; Elgenidy A; Hashim M; Awad AK; Jalal PK
    Rev Med Virol; 2022 Nov; 32(6):e2353. PubMed ID: 35441759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining hepatitis B core-related and surface antigens at end of nucleos(t)ide analogue treatment to predict off-therapy relapse risk.
    Hsu YC; Nguyen MH; Mo LR; Wu MS; Yang TH; Chen CC; Tseng CH; Tai CM; Wu CY; Lin JT; Tanaka Y; Chang CY
    Aliment Pharmacol Ther; 2019 Jan; 49(1):107-115. PubMed ID: 30450681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.
    Wang L; Cao X; Wang Z; Gao Y; Deng J; Liu X; Zhuang H
    J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30355757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M; Shirasaki T; Terashima T; Kawaguchi K; Nakamura M; Oishi N; Wang X; Shimakami T; Okada H; Arai K; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Kaneko S
    J Infect Dis; 2016 Apr; 213(7):1096-106. PubMed ID: 26621908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.